The drug is associated with a high incidence of adverse reactions (excessive salivation and partial to complete loss of appetite) purportedly because of its brassy taste (2,3)

The recent phase 2 trial of tirzepatide in patients with MASH provides support for the therapeutic potential of GIPpathway modulation in cardiometabolic disease and demonstrates how GIP signaling, when cotargeted with GLP-1RA, may contribute to weight loss, improved metabolic outcomes, and possibly cardiovascular protection ( However, these benefits are accompanied by concerns about side effects, cost, long-term sustainability and, above all, the loss of lean mass, which may be mitigated by concurrent exercise ( Exercise and lifestyle interventions remain foundational for obesity and metabolic disease management, offering broad health benefits, but are often limited by adherence and modest long-term weight loss ( Recent randomized controlled trials and meta-analyses suggest that combining GLP-1RAs with exercise may yield additive or synergistic effects on weight loss and metabolic syndrome severity as well as on oxidative stress and inflammation

Maximum effects are typically reached within 2-3 months
Benefits of Qsymia at JourneyLite Patients choose JourneyLite for Qsymia treatment because we offer: Physician-directed evaluation and monitoring Personalized dosing and adjustments Ongoing weight loss and nutrition guidance Access to alternative medications or surgery if needed Our integrated approach ensures you are using the right tool for your goals , not just the most advertised one